Pharmaxis Ltd

Headquarters: Frenchs Forest, NSW, Australia

Employees: 66

CEO: Mr. Gary Jonathan Phillips BPharm, MBA

ASX: PXS -5.88%

Market Cap

A$19.5 Million

AUD as of Jan. 1, 2024

US$13.3 Million

Market Cap History

Pharmaxis Ltd market capitalization over time

Evolution of Pharmaxis Ltd market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Pharmaxis Ltd

Detailed Description

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting myelofibrosis and other cancers, and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.

Top 1-year algo backtest: +284.14%

$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Pharmaxis Ltd has the following listings and related stock indices.

Stock: ASX: PXS wb_incandescent

Stock: FSX: UUD wb_incandescent



20 Rodborough Road

Frenchs Forest, NSW 2086


Phone: 61 2 9454 7200

Fax: 61 2 9451 3622